but has the market / sales potential changed? I would say given eylea and lucentis have gone off patent (cheaper), it would make opt more easily to prescribe and afford for end users (ie. their health providers)
maybe opt could be used with avanstin off label too?
but has the market / sales potential changed? I would say given...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $398.3M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 38.5¢ | 35.5¢ | $685.8K | 1.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 61550 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 48038 | 9 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |